Phenylbutyrate/Genistein Duotherapy in Delta F508-Homozygous(for Cystic Fibrosis)

This study has been completed.
Sponsor:
Collaborators:
Cystic Fibrosis Foundation
Information provided by:
Children's Hospital of Philadelphia
ClinicalTrials.gov Identifier:
NCT00016744
First received: May 31, 2001
Last updated: January 8, 2009
Last verified: January 2009
  Purpose

We are testing a new combination of medicines, to determine if they could be used to treat cystic fibrosis (CF). Subjects with CF who have two copies of the most common mutation (change) found in patients with CF called DF508. CF is caused by a lack of chloride movement in the nose, sinuses, lungs, intestines, pancreas and sweat glands. We are conducting this study to determine the safety of using a combination of two medicines, Phenylbutyrate and Genistein, to improve the ability of the cells lining the nose to regulate movement of salt (chloride) and water in people with CF.

Phenylbutyrate has been extensively used to treat patients with rare metabolic diseases (which are very different from CF), Phenylbutyrate is an investigational drug for the purpose of this study. Genistein is a naturally occurring substance that is found in food products such as soy and tofu, but is also an investigational drug for this study. Both drugs may be able to restore normal chloride movements in body organs and glands. We will be studying salt and water in the nose movement by a technique called nasal transepithelial potential difference (NPD).


Condition Intervention Phase
Cystic Fibrosis
Drug: Sodium 4-Phenylbutyrate (4PBA)
Drug: Unconjugated Isoflavones 100 (PTI G-4660, 87% Genistein)
Drug: Placebo
Phase 1
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Basic Science
Official Title: A Pilot Trial of Phenylbutyrate/Genistein Duotherapy in Delta F508-Homozygous Cystic Fibrosis Patients

Resource links provided by NLM:


Further study details as provided by Children's Hospital of Philadelphia:

Primary Outcome Measures:
  • The basis of analysis for the primary outcome measure will be the comparison of data from both the standard CF NPD protocol compared to a modified NPD protocol including the perfusion of Genistein. [ Time Frame: All visits ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Interval history, physical and mental status examination. [ Time Frame: Every visit ] [ Designated as safety issue: Yes ]
  • Laboratory Evaluations [ Time Frame: Every visit ] [ Designated as safety issue: Yes ]
  • Spirometry Data [ Time Frame: Every visit ] [ Designated as safety issue: Yes ]

Enrollment: 12
Study Start Date: September 2001
Study Completion Date: October 2005
Primary Completion Date: October 2005 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: 1

Subjects will be randomized to receive either the Phenylbutyrate or placebo tablets for 4 days

Every participant will receive Genistein during the NPD.

Drug: Sodium 4-Phenylbutyrate (4PBA)
The standard oral adult dose is 20g/day (tablets) for 4 days.
Drug: Unconjugated Isoflavones 100 (PTI G-4660, 87% Genistein)
Every participant will be administered a perfusion of 50 MicroM of Genistein during the modified NPD procedure.
Placebo Comparator: 2 Drug: Unconjugated Isoflavones 100 (PTI G-4660, 87% Genistein)
Every participant will be administered a perfusion of 50 MicroM of Genistein during the modified NPD procedure.
Drug: Placebo
The placebo dose will match the oral tablets in arm 1, maintaining the study blind.

Detailed Description:

Subjects will be randomized to receive either the Phenylbutyrate or placebo tablets for 1 week, with a 2 out of 3 chance of receiving Phenylbutyrate at a standard adult dose, with visits on study days 1, 4, and 7. The study will last an additional 2 weeks to determine whether the effects of the Phenylbutyrate or Placebo persist for any length of time, with visits on study days 14 and 21. Every participant will receive the Genistein during the NPD on days 1 and 7. The dose of Genistein used will not be escalated and will be the same for every participant.

Safety evaluations at each visit will include a history, and physical exam and mental status exam, blood and urine tests, and lung function tests. The main physiologic outcome of the trial will be the assessment of salt and water transport NPD. In this way, we will assess whether genistein enhances the effect of phenylbutyrate to improve chloride transport in the nose by topical application of genistein to the nasal mucosa during the NPD procedure on study days 1 and 7.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Able to communicate with pertinent staff, able to understand and willing to comply with the requirements of the trial, and able and willing to give informed consent.
  2. Willing to practice a reliable and study-accepted method of contraception during the study.
  3. Diagnosis of cystic fibrosis consisting of both:

    1. clinical manifestations of cystic fibrosis and
    2. cystic fibrosis genotype homozygous for Delta F508 and sweat sodium or chloride > 60 mEq/L
  4. Oxyhemoglobin saturation greater than or equal to 92% while breathing room air

Exclusion Criteria:

  1. Underlying diseases likely to limit life span and/or increase risk of complications:

    1. Cancer requiring treatment in the past 5 years, with the exception of cancers that have been cured, or in the opinion of the investigator, carry a good prognosis such as non-melanoma skin cancer, papillary thyroid carcinoma, and cervical cancer in situ.
    2. GI disease

    i. Inflammatory bowel disease requiring treatment in the past year ii. elevations in ALT or AST levels to greater than 3 times the upper limit of normal

  2. Conditions or behaviors likely to affect the conduct of the study

    1. Current or anticipated participation in another intervention research project
    2. Recent (with 2 months) sinus surgery or nasal polypectomy
    3. Currently pregnant or less than 3 months post-partum
    4. Currently nursing or within 6 weeks of having completed nursing
    5. Unwilling to undergo pregnancy testing or to report possible or confirmed pregnancy promptly during the course of the study
    6. Unwilling to use a reliable contraceptive method for two months after the completion of the study.
    7. Major psychiatric disorder, which, in the opinion of the investigators, would impede conduct of the study, e.g., alcoholism
    8. Other condition, which, in the opinion of the investigators, would impede conduct of the study.
  3. Glucocorticoids other than topical, ophthalmic, and inhaled preparations.
  4. Conditions that would place the patient at an increased risk for complications:

    1. Pneumothorax within the last 12 months
    2. Uncontrolled diabetes
    3. Asthma or allergic bronchopulmonary aspergillosis requiring systemic glucocorticoid therapy within the last two months
    4. Sputum culture growing a pathogen that does not have in vitro sensitivity to at least two types of antibiotics which could be administered to the patient
    5. History of major hemoptysis: (Greater than 240 mL of blood within a 24-hour period within the last 12 months).
  5. Medication use or conditions not specifically mentioned above, including severe or end stage CF lung disease, that may serve as criteria for exclusion at the discretion of the investigators.
  6. History of significant cardiovascular disease, such as myocardial infarction, congestive heart failure, unstable arrhythmia, or uncontrolled hypertension.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00016744

Sponsors and Collaborators
Children's Hospital of Philadelphia
Cystic Fibrosis Foundation
Investigators
Principal Investigator: Ronald Rubenstein, M.D., PhD. Children's Hospital of Philadelphia
  More Information

No publications provided

Responsible Party: Ronald Rubenstein, M.D., PhD., The Children's Hospital of Philadelphia
ClinicalTrials.gov Identifier: NCT00016744     History of Changes
Other Study ID Numbers: NCRR-M01RR00240-1765, IRB#2000-10-2189
Study First Received: May 31, 2001
Last Updated: January 8, 2009
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Cystic Fibrosis
Fibrosis
Digestive System Diseases
Genetic Diseases, Inborn
Infant, Newborn, Diseases
Lung Diseases
Pancreatic Diseases
Pathologic Processes
Respiratory Tract Diseases
4-phenylbutyric acid
Genistein
Anticarcinogenic Agents
Antineoplastic Agents
Enzyme Inhibitors
Estrogens
Estrogens, Non-Steroidal
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Phytoestrogens
Protective Agents
Protein Kinase Inhibitors
Therapeutic Uses

ClinicalTrials.gov processed this record on October 29, 2014